The Ministry of Ayush asks Patanjali to take down the advertisement of Covid-19 drugs, as it’s unapproved

0
149

Hours after Yoga guru Ramdev launched what he claimed were the first ayurvedic medicines to cure COVID-19, The Ministry of Ayush asked Patanjali Ayurved to stop advertising the drugs due to the lack of requisite approval. The legal provisions cited in the ministry statement also indicate that Patanjali cannot sell the product as of now.

The Ministry of Ayush said, They were unaware of the facts and details of Patanjali’s claims of virus medicine named ‘Coronil’.

“In order to make this Ministry aware of the facts of the aforesaid news and verify the claims,  Patanjali Ayurved Ltd. has been asked to provide at the earliest details of the name and composition of the medicines being claimed for Covid treatment; site(s)/hospital(s), where the research study was conducted for Covid-19; protocol, sample size, Institutional Ethics Committee clearance, CTRI registration  and results data of the study (ies) and stop advertising/publicising such claims till the issue is duly examined.”

“Ministry has also requested concerned State Licensing Authority of Uttarakhand Government to provide copies of license and product approval details of the Ayurvedic medicines being claimed for the treatment of COVID -19.” As per officials.

Patanjali claimed that their drugs — ‘Coronil’ and ‘Swasari’– had shown 100 per cent favourable results during clinical trials on Covid-19 infected patients, except those on a life support system, at Patanjali Yogpeeth in Haridwar, as per news agency.

Earlier today, Patanjali Founder Swami Ramdev and Managing Director Acharya Balkrishna hosted a press conference claiming the consumer goods company had developed a medicine to treat Covid-19.

Patanjali has now been cautioned by the ministry that advertising such a drug, including an Ayurvedic medicine, is regulated by the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules and directives issued by the central government pursuant to the virus outbreak.

Murali Neelakantan, a lawyer who has worked in the pharmaceutical industry, said based on the statement issued by AYUSH ministry it is fair to deduce that the product has not been licensed under Chapter IVA of the Drugs & Cosmetics Act and Rule 158(B) of the Drugs & Cosmetics Rules.As a consequence, the manufacture or sale of this product is punishable under section 33I of the Drugs Act,” Neelakantan said in an email comment.

LEAVE A REPLY

Please enter your comment!
Please enter your name here